Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.…
Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026
Zhengye Biotechnology Holding (NASDAQ: ZYBT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 269 employees.
The shares were at 1.480 USD on 20 November 2026, down 31.2% over 52 weeks. Its 52-week range is 0.6160 USD to 8.010 USD: the price is 81.5% below the high and 140.3% above the low.
Its market capitalisation is 70.14M USD.
Zhengye Biotechnology Holding reports return on equity of -27.9%, an operating margin of -59.5% and revenue down 18.3% year over year.
Its debt exceeds its cash by 45.73M CNY, a debt-to-equity ratio of 0.30. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.